Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Selection of Color Additives: A Regulatory View

Author(s):  Kumar Anuj, Dureja Harish, Madan Anil K

Issue:  Jul/Aug 2012 - Volume 16, Number 4
View All Articles in Issue

Page(s):  304-309

Selection of Color Additives: A Regulatory View Page 1
Selection of Color Additives: A Regulatory View Page 2
Selection of Color Additives: A Regulatory View Page 3
Selection of Color Additives: A Regulatory View Page 4
Selection of Color Additives: A Regulatory View Page 5
Selection of Color Additives: A Regulatory View Page 6

Download in electronic PDF format for $75

Abstract:  Color additives have a unique place in the categories of the excipients. However, most of the color additives are complex heterogeneous organic compounds. In pharmaceuticals, colors are used in various oral (solid, liquid) and topical dosage form. Different regulatory authorities have their own specific set of regulation for registration, approval, and control of color additives. However, at this time of globalization, selection of appropriate color is not an easy task when a company wants to sale its product in many countries. In this article, the authors have explored various important factors which should be considered in the selection of color additives.

Related Keywords: Anuj Kumar, M Pharm, Harish Dureja, M Pharm, PhD, Anil K. Madan, PhD, color additives, dyes, colorants, drug safety, regulation, U.S. Food and Drug Administration, FDA, pigments, psychological effects, compatibility, stability

Related Categories: EXCIPIENTS, LEGAL

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Selection of Color Additives: A Regulatory View
Kumar Anuj
, Dureja Harish, Madan Anil K
Jul/Aug 2012
Pg. 304-309

Color Additives: Legislative Perspective in the United States, Europe, Australia, and India
Kumar Anuj
, Madan Anil K
Jul/Aug 2014
Pg. 293-300

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

Documentation: Records and Reports
Akers Michael J
Sep/Oct 2017
Pg. 373-380

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1
Allen Loyd V Jr
Jul/Aug 2007
Pg. 350-351

Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Kupiec Tom
, Kemp Jesse
Jul/Aug 2007
Pg. 326-327

The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists
Parks Kenneth Chase
, Bernard Brian, Cogdill Christopher Blake
Sep/Oct 2015
Pg. 377-380

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers
Allen Loyd V Jr
, Williams LaVonn A
Jul/Aug 2012
Pg. 294-298

U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013
Miller David G
Jan/Feb 2014
Pg. 35-36

Basics of Compounding: Tips and Hints, Part 4: Lollipops/Lozenges, Gummy Bears, Patches, Flavoring/Coloring, Sweeteners, and Packaging
Allen Loyd V Jr
Jul/Aug 2014
Pg. 318-319

Return to Top